Financial Performance - Operating revenue for the reporting period was ¥414,928,220.67, reflecting a year-on-year growth of 1.83%[7] - Net profit attributable to shareholders was ¥38,219,853.21, a decrease of 12.59% compared to the same period last year[7] - Basic earnings per share decreased by 14.29% to ¥0.06[7] - The weighted average return on equity was 2.32%, down 13.75% year-on-year[7] - The company reported a net profit attributable to shareholders after deducting non-recurring gains and losses of ¥36,600,347.90, a decrease of 13.88%[7] - The company reported a significant increase in tax refunds received, amounting to ¥19,623,693.82, an increase of 348.83%[19] - The company’s cash dividends and interest payments increased by ¥159,940,240.91, a rise of 257.16%, due to higher cash dividends distributed to shareholders[20] - The company reported a net profit margin improvement, with net profit for the period not explicitly stated but inferred from revenue growth and cost management strategies[48] Assets and Liabilities - Total assets at the end of the reporting period reached ¥3,347,223,843.30, an increase of 0.36% compared to the previous year[7] - The company's current assets decreased to 1,243,519,139.71 yuan from 1,315,694,940.70 yuan at the end of 2018, reflecting a decline of approximately 5.5%[38] - The company's non-current assets totaled 2,103,704,703.59 yuan, compared to 2,019,659,162.42 yuan at the end of 2018, showing an increase of about 4.2%[39] - Total liabilities of the company reached CNY 947,170,292.39, compared to CNY 854,990,788.11 in the previous year, indicating a rise of 10.76%[46] - The total non-current liabilities decreased to CNY 420,559,900.64 from CNY 453,074,492.14, reflecting a reduction of 7.15%[46] - Total liabilities reached CNY 1,555,962,970.72, with current liabilities at CNY 1,102,888,478.58 and non-current liabilities at CNY 453,074,492.14[74] Shareholder Information - The total number of shareholders at the end of the reporting period was 35,282[11] - The largest shareholder, Inner Mongolia Jinhai Construction Installation Co., Ltd., held 38.05% of the shares[11] - The company’s controlling shareholder plans to reduce its shareholding, as notified on August 19, 2019[24] - The major shareholder, Shangyin Fund, plans to continue reducing its stake by up to 12,705,793 shares, representing no more than 2% of the total share capital[27] Cash Flow - Net cash flow from operating activities increased significantly by 316.67% to ¥94,577,459.04[7] - Net cash flow from operating activities increased by ¥150,550,334.47, an increase of 191.64%, driven by sales revenue growth and effective collection of receivables[19] - The company reported a cash inflow from operating activities of CNY 1.29 billion, compared to CNY 1.05 billion in the previous period[63] - The net cash flow from operating activities for Q3 2019 was CNY 229,109,227.22, a significant increase from CNY 78,558,892.75 in Q3 2018, representing a growth of approximately 191.5%[64] - Total cash inflow from operating activities reached CNY 1,342,617,565.51, compared to CNY 1,103,997,758.39 in the previous year, indicating an increase of about 21.7%[64] Research and Development - Research and development expenses increased by ¥19,126,494.68, a rise of 76.09%, as the company enhanced R&D investments across its business segments[17] - Research and development expenses increased significantly to CNY 13,432,935.06, compared to CNY 4,953,323.06 in Q3 2018, marking a growth of 171.36%[48] - The company plans to continue investing in R&D to enhance product offerings and market competitiveness[48] Financial Management - Financial expenses increased by ¥17,180,896.09, a surge of 207.10%, due to a higher average amount of bank loans and corresponding interest expenses[17] - The financial expenses for the third quarter were reported as -¥13,621,506.42, a decrease from -¥17,743,230.12 in the previous year[52] - The company recorded a credit impairment loss of -¥485,467.66 during the quarter[52] - The total assets impairment loss was -¥332,787.00, contributing to the overall financial performance[52] Investment Activities - The company plans to increase capital in its subsidiary, Jinhe Youben, raising its registered capital from ¥10 million to ¥50 million[25] - The company has increased its investment in its subsidiary, Hangzhou Youben Animal Vaccine Co., Ltd., raising its registered capital from 77.92 million yuan to 200 million yuan[29] Inventory and Receivables - Accounts receivable decreased by ¥53,812,189.51, a reduction of 51.16%, mainly due to a decrease in payments settled by acceptance bills[15] - The company's inventory rose to 391,554,980.87 yuan, up from 366,049,329.28 yuan, marking an increase of approximately 7%[38] - The company reported a decrease in accounts receivable from 300,373,769.73 yuan to 277,023,249.78 yuan, a decline of approximately 7.7%[38]

Financial Performance - The company's operating revenue for the first half of 2019 was CNY 833,702,310.89, representing an increase of 18.50% compared to CNY 703,552,615.17 in the same period last year[16]. - The net profit attributable to shareholders of the listed company was CNY 105,038,435.48, up 23.31% from CNY 85,178,965.69 year-on-year[16]. - The net profit after deducting non-recurring gains and losses was CNY 99,430,945.90, reflecting a growth of 28.24% compared to CNY 77,532,391.89 in the previous year[16]. - Basic earnings per share rose to CNY 0.17, a 30.77% increase from CNY 0.13 in the previous year[16]. - Operating profit reached 130.74 million CNY, reflecting a year-on-year increase of 29.04%[34]. - The company's overall operating income was CNY 833.702 million, reflecting an 18.50% increase compared to the previous year[42]. - The total comprehensive income for the first half of 2019 was CNY 132,022,296.17, compared to CNY 82,211,544.29 in the first half of 2018, indicating a growth of 60.8%[153]. - The total revenue for the first half of 2019 was 1,677 million yuan, representing a decrease of 53.78% compared to the previous period[163]. Cash Flow and Financial Position - The net cash flow from operating activities increased significantly by 140.83%, reaching CNY 134,531,768.18, compared to CNY 55,860,584.37 in the same period last year[16]. - Cash and cash equivalents at the end of the reporting period were ¥416,498,603.90, up from ¥308,612,288.05, reflecting a 2.33% increase in total assets[51]. - The company reported a net cash outflow from financing activities of CNY 146.345 million, a decrease of 424.60% year-on-year, largely due to increased cash dividends paid to shareholders[43]. - The cash flow from financing activities showed a net outflow of -CNY 146,345,025.69, compared to -CNY 27,896,354.60 in the previous year, indicating a decline in financing efficiency[157]. - The cash balance at the end of the reporting period was RMB 416,498,603.98, down from RMB 491,811,925.20, a decrease of about 15.2%[136]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,338,610,237.31, a slight increase of 0.10% from CNY 3,335,354,103.12 at the end of the previous year[16]. - Total liabilities increased to CNY 1.62 billion as of June 30, 2019, compared to CNY 1.56 billion at the end of 2018[144]. - Short-term borrowings rose to ¥987,315,039.40, representing 29.57% of total liabilities, an increase of 7.65% compared to the previous year[52]. - The company's total assets at the end of the reporting period amounted to 5,230.1 million CNY, with a total equity of 1,728.3 million CNY[169]. Revenue Sources - Revenue from animal feed additives was ¥505,661,565.14, accounting for 60.65% of total revenue, with a year-on-year growth of 15.88%[44]. - Sales revenue from feed additives amounted to 505.66 million CNY, representing a growth of 15.88% year-on-year[34]. - The veterinary vaccine business generated sales revenue of CNY 35.135 million, a decrease of CNY 29.648 million or 45.77% year-on-year, primarily due to reduced demand from the African swine fever epidemic[35]. - The agricultural product processing business reported revenue of CNY 216.6598 million, an increase of CNY 58.0994 million or 36.64% year-on-year, driven by expanded downstream market demand[35]. Research and Development - Research and development investment increased by 22.23% year-on-year, totaling CNY 40.6407 million, reflecting the company's commitment to innovation[42]. - Research and development expenses for the first half of 2019 were CNY 30.83 million, a significant increase of 52.5% from CNY 20.18 million in the first half of 2018[146]. - The R&D expenses for the first half of 2019 were 1,599.3 million CNY, which is 4.96% of total revenue, highlighting the company's commitment to innovation[171]. Market and Strategic Focus - The company is focusing on adjusting its product structure and expanding into overseas markets in response to the ongoing impact of African swine fever[26]. - The company plans to continue expanding its wastewater treatment operations and enhance its product offerings in the animal health sector[46]. - The company plans to focus on expanding its market presence and enhancing product development in the upcoming quarters[163]. - The company has initiated new strategies for technological advancements and product innovation to drive future growth[163]. Risks and Challenges - The company has outlined potential risks and countermeasures in its report, emphasizing the importance of investor awareness regarding these risks[4]. - The ongoing African swine fever epidemic has led to a significant decrease in the breeding stock of pigs, adversely affecting the demand for the company's vaccine products[65]. - The company faces risks from policy changes regarding feed additives, which may impact product sales due to regulatory shifts[65]. - The company is taking measures to mitigate the impact of rising raw material prices, particularly corn, which constitutes a significant portion of product costs[65]. Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares[5]. - The company held its first extraordinary shareholders' meeting in 2019 with a participation rate of 39.86% on January 14, 2019[68]. - The total number of ordinary shareholders at the end of the reporting period was 33,319, with the largest shareholder holding 38.05% of the shares[120]. Environmental and Social Responsibility - The company invested 2.5 million yuan in poverty alleviation efforts, focusing on industrial development and employment transfer in partnership with local villages[103]. - The company has received multiple environmental impact assessment approvals and permits for its construction projects, ensuring compliance with environmental regulations[97]. - The company has been awarded the "Demonstration Base for Third-Party Environmental Pollution Governance" by local environmental protection authorities[100].

Financial Performance - Revenue for Q1 2019 was CNY 384,630,239.08, representing a 13.95% increase compared to CNY 337,548,703.22 in the same period last year[7] - Net profit attributable to shareholders was CNY 37,734,004.99, up 22.44% from CNY 30,819,150.40 year-over-year[7] - Net profit excluding non-recurring items reached CNY 35,778,746.87, a significant increase of 43.52% compared to CNY 24,930,082.05 in the previous year[7] - Basic earnings per share increased by 20.00% to CNY 0.06 from CNY 0.05 in the same quarter last year[7] - The company reported a total comprehensive income of CNY 34,066,575.69 for Q1 2019, compared to CNY 30,469,344.37 in the same quarter last year[42] - The company's operating profit for Q1 2019 was approximately ¥58.11 million, compared to ¥21.44 million in the same period last year, representing an increase of 171.5%[45] - The net profit for Q1 2019 reached approximately ¥49.33 million, up from ¥18.18 million in Q1 2018, marking a growth of 171.5%[46] - Basic and diluted earnings per share for Q1 2019 were both ¥0.08, compared to ¥0.03 in the same period last year, indicating an increase of 166.7%[46] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,446,045,189.92, reflecting a 3.32% increase from CNY 3,335,354,103.12 at the end of the previous year[7] - Total current assets increased to ¥1,425,674,790.19 as of March 31, 2019, up from ¥1,315,694,940.70 at the end of 2018, representing a growth of approximately 8.5%[31] - Total liabilities increased to ¥1,631,237,826.77 from ¥1,555,962,970.72, representing a growth of approximately 4.8%[32] - The total liabilities as of Q1 2019 amounted to CNY 968,678,901.22, compared to CNY 854,990,788.11 in the same period last year, reflecting a growth of 13.27%[38] - The company's equity attributable to shareholders increased to ¥1,714,678,437.43 from ¥1,677,942,572.62, reflecting a growth of approximately 2.2%[33] Cash Flow - The net cash flow from operating activities decreased by 65.02% to CNY 3,731,560.95 from CNY 10,666,985.40 in the same period last year[7] - The total cash inflow from operating activities was approximately ¥376.07 million, compared to ¥361.41 million in the previous year, indicating a year-over-year increase of 4.6%[49] - The net cash flow from operating activities was approximately ¥3.73 million, down from ¥10.67 million in the same period last year, reflecting a decrease of 65.0%[49] - The company reported cash inflow from financing activities of approximately ¥380.00 million, an increase from ¥327.43 million in the previous year, representing a growth of 16.0%[50] - The net cash flow from financing activities improved to CNY 118,356,326.55, compared to a negative cash flow of CNY 23,172,630.52 in Q1 2018[54] Expenses and Investments - Research and development expenses increased by 9,748,650.90 yuan, an increase of 102.76%, primarily due to increased investment in R&D across various business segments to enhance market competitiveness[15] - Total operating costs for Q1 2019 were CNY 340,359,134.17, up 11.43% from CNY 305,421,167.03 in Q1 2018[39] - Cash outflow for purchasing goods and services was CNY 122,192,716.84, significantly higher than CNY 60,766,059.88 in Q1 2018, indicating increased operational costs[53] - Cash outflow for employee payments was CNY 36,651,823.74, compared to CNY 30,871,566.23 in the previous year, reflecting a 18.7% increase[53] - The company reported a cash outflow from investing activities of approximately ¥29.81 million, compared to ¥36.63 million in the previous year, indicating a decrease of 18.8%[50] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 30,666[10] - The largest shareholder, Inner Mongolia Jinhai Construction Installation Co., Ltd., held 38.05% of the shares, amounting to 241,758,670 shares[10] - The company’s non-public issuance of 90,689,655 shares, accounting for 14.2753% of the total share capital, was released for trading on February 11, 2019[20]

Financial Performance - In 2018, the company's operating revenue reached ¥1,628,890,098.36, an increase of 11.73% compared to ¥1,457,826,359.89 in 2017[14] - The net profit attributable to shareholders was ¥163,628,881.41, representing a significant growth of 50.92% from ¥108,423,892.06 in the previous year[14] - The net profit after deducting non-recurring gains and losses was ¥152,255,616.24, up 60.15% from ¥95,070,633.81 in 2017[14] - The net cash flow from operating activities surged by 329.95% to ¥117,174,643.71, compared to ¥27,253,028.88 in 2017[14] - Basic earnings per share increased by 52.94% to ¥0.26, up from ¥0.17 in the previous year[14] - Total assets at the end of 2018 amounted to ¥3,335,354,103.12, a 12.68% increase from ¥2,959,911,864.10 at the end of 2017[14] - The net assets attributable to shareholders rose by 9.92% to ¥1,677,942,572.62, compared to ¥1,526,518,658.25 in 2017[14] Business Expansion and Operations - The company expanded its business scope in 2018 to include the production of calcium premix for oxytetracycline and mixed feed additives[13] - The main business areas include veterinary feed additives, veterinary vaccines, and industrial wastewater treatment, with no significant changes reported during the reporting period[23] - The company operates under a third-party governance model for industrial wastewater treatment, which is expected to enhance treatment efficiency and reduce costs[25] - The company has established a diversified industrial layout in animal health, including feed additives, veterinary vaccines, and veterinary chemical drugs[39] Revenue Breakdown - The feed additive business achieved revenue of CNY 1,042.13 million, a year-on-year increase of 6.45%[40] - The veterinary biological products segment generated revenue of CNY 123.61 million, up 31.15% from the previous year, with a gross margin increase of 13.98%[43] - The wastewater treatment business recorded revenue of CNY 101.80 million, reflecting a 19% year-on-year growth[46] - The starch and related products segment achieved revenue of CNY 331.75 million, a 14.83% increase compared to the previous year[47] - Domestic sales accounted for 63.73% of total revenue, while international sales made up 36.27%[49] Cost and Expenses - The total cost of raw materials for animal feed additives in 2018 was ¥299,706,207.06, accounting for 53.19% of the operating costs, a decrease of 0.84% compared to 2017[57] - The labor cost for animal feed additives increased to ¥71,165,654.12, representing 12.63% of operating costs, up by 0.20% year-on-year[57] - Sales expenses increased by 16.12% to ¥131,786,770.97 due to increased sales personnel compensation and market development costs[64] - Management expenses rose by 13.54% to ¥203,896,040.99, driven by performance increases and regulatory registration costs[64] - R&D expenses increased by 20.84% to ¥40,512,065.45, reflecting the company's commitment to enhancing market competitiveness[64] Shareholder and Dividend Information - The company plans to distribute a cash dividend of ¥2.50 per 10 shares, based on a total share capital of 635,289,655 shares as of December 31, 2018[4] - The cash dividend per 10 shares is CNY 2.50, with a total of 635,289,655 shares as the base for distribution[99] - The total distributable profit for the year was CNY 453,604,715.67, with the cash dividend accounting for 100% of the profit distribution[99] Environmental and Social Responsibility - The company has received recognition for its environmental protection efforts, including being awarded as a "Demonstration Base for Third-Party Pollution Control" by local environmental authorities[133] - The company actively participates in social welfare initiatives, including poverty alleviation and support for underprivileged students and employees[134] - The company adheres to pollution discharge standards, with no reported exceedances in emissions for key pollutants[138] Governance and Compliance - The company has established a comprehensive corporate governance structure and internal control system to protect the rights of shareholders and creditors, ensuring timely and accurate information disclosure[131] - The audit firm, Ruihua Certified Public Accountants, has been engaged for 10 consecutive years, with an audit fee of 1.3 million yuan[108] - There were no significant accounting errors requiring restatement during the reporting period[106] Future Outlook and Strategy - Future outlook indicates a projected revenue growth of 15% for 2019, driven by new product launches and market expansion strategies[173] - The company is considering strategic acquisitions to enhance its product portfolio and increase operational efficiency[176] - The management team has a strong background in the industry, with an average of over 15 years of experience among senior executives[175]

证券代码：002688 证券简称：金河生物 公告编号：2018-060 金河生物科技股份有限公司 2018 年第三季度报告正文 1 金河生物科技股份有限公司 2018 年第三季度报告正文 金河生物科技股份有限公司 2018 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人王东晓、主管会计工作负责人牛有山及会计机构负责人(会计主 管人员)周立航声明：保证季度报告中财务报表的真实、准确、完整。 2 金河生物科技股份有限公司 2018 年第三季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 3,191,328,510.37 | 2,959,911,864.10 | | 7.82% | | 归属 ...

Financial Performance - The company's operating revenue for the first half of 2018 was CNY 703,552,615.17, representing a 9.82% increase compared to CNY 640,651,552.54 in the same period last year[16]. - The net profit attributable to shareholders was CNY 85,178,965.69, up 10.90% from CNY 76,809,220.02 year-on-year[16]. - The net cash flow from operating activities increased significantly by 138.93%, reaching CNY 55,860,584.37 compared to CNY 23,379,329.00 in the previous year[16]. - The total assets at the end of the reporting period were CNY 3,041,861,887.51, a 2.77% increase from CNY 2,959,911,864.10 at the end of the previous year[16]. - The net assets attributable to shareholders increased by 4.43%, amounting to CNY 1,594,100,948.42 compared to CNY 1,526,518,658.25 at the end of the last year[16]. - The basic earnings per share rose to CNY 0.13, an increase of 8.33% from CNY 0.12 in the same period last year[16]. - Operating profit reached 101.32 million yuan, reflecting an increase of 11.24% year-on-year[27]. - The company achieved operating revenue of 703.55 million yuan, an increase of 9.82% compared to the same period last year[27]. - The company reported a government subsidy of CNY 8,933,749.76 during the period[20]. - The weighted average return on net assets was 5.44%, up from 5.06% in the previous year[16]. Revenue Breakdown - The sales revenue from veterinary vaccines was 64.78 million yuan, marking a significant increase of 44.18% year-on-year[34]. - Revenue from animal feed additives reached CNY 436.37 million, an increase of 45.16% year-on-year[44]. - Revenue from veterinary biological products grew by 58.00% year-on-year, totaling CNY 64.78 million, driven by breakthroughs in vaccine sales[44]. - Domestic sales accounted for 66.44% of total revenue, increasing by 28.68% year-on-year, while international sales decreased by 14.88%[42]. - Foreign sales increased by 43.26% year-on-year to CNY 236.13 million, despite a decline in previous quarters[44]. - The company's revenue from environmental protection services rose by 31.82% year-on-year, attributed to increased wastewater treatment contracts[44]. Cost and Expenses - Total operating costs amounted to CNY 610,750,935.69, up from CNY 554,158,517.22, reflecting a growth of 10.21%[143]. - Sales expenses amounted to 48.41 million, an increase of 10.72% year-on-year, primarily due to the expansion of the sales team and increased marketing efforts[37]. - Management expenses reached 100.29 million, an increase of 18.75% year-on-year, attributed to the increase in the number of management personnel and rising employee compensation[37]. - Financial expenses decreased by 36.93% to 16.70 million, mainly due to significant foreign exchange gains and higher average bank borrowing costs[38]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 3.04 billion, with cash and cash equivalents at CNY 308.61 million, representing 10.15% of total assets[49]. - Short-term borrowings increased to CNY 666.90 million, accounting for 21.92% of total assets, up from 16.02% in the previous year[49]. - Current liabilities totaled CNY 892,076,626.02, an increase from CNY 855,124,288.22, reflecting a rise of 4.03%[135]. - Non-current liabilities decreased to CNY 449,899,288.84 from CNY 467,468,972.11, a decline of 3.63%[135]. - The company's total equity increased to CNY 1,699,885,972.65 from CNY 1,637,318,603.77, marking a growth of 3.81%[136]. Research and Development - The company invested 33.25 million in R&D, a 35.25% increase year-on-year, focusing on multiple vaccine projects[40]. - The company is focusing on strategic adjustments to enhance product value and extend the industrial chain[34]. - The veterinary chemical drugs segment is actively pursuing new product development, although market expansion is still in progress[35]. Environmental Initiatives - The company has invested heavily in environmental protection, establishing itself as a leader in industrial wastewater treatment and resource utilization[101]. - The company installed 13 tail gas photocatalytic oxidation treatment devices in five fermentation workshops and 5 devices in the extraction workshop during the reporting period[100]. - The total COD emissions from Inner Mongolia Jinhe Environmental Protection Technology Co., Ltd. were 42.44 tons, below the approved limit of 63.87 tons[99]. - The company’s SO2 emissions were recorded at 121.551 tons, significantly below the limit of 436.39 tons[99]. - The company’s NOx emissions were 145.277 tons, also well within the limit of 436.39 tons[99]. Shareholder Information - The company held its first extraordinary shareholders' meeting in 2018 with a participation rate of 40.36% on January 26, 2018[69]. - The annual shareholders' meeting for 2017 had a participation rate of 41.04% and was held on April 13, 2018[69]. - The company plans not to distribute cash dividends or issue bonus shares for the half-year period[70]. - The total number of ordinary shareholders at the end of the reporting period was 35,092[116]. Risks and Challenges - The company faces risks from rising raw material prices, particularly corn, which significantly impacts product costs, and is focusing on cost control and market analysis[65]. - The company is also addressing risks related to exchange rate fluctuations and new product market development, ensuring a strong sales team and market-oriented strategies[66]. - Regulatory changes in the veterinary medicine industry pose a risk, and the company is committed to adapting to these changes while enhancing its product offerings[66]. Corporate Governance - There were no violations of commitments by the actual controller and shareholders during the reporting period[71]. - The company has committed to not engage in any competitive activities with its own business during the reporting period[72]. - The company has not conducted any audits for its half-year financial report[76]. Financial Reporting - The financial report for the first half of 2018 was not audited[131]. - The company's financial statements reflect the impact of exchange rate fluctuations on cash flows, which are reported separately in the cash flow statement[195]. - The company recognizes deferred tax assets related to deductible temporary differences if new information indicates that the economic benefits can be realized within 12 months post-acquisition, reducing goodwill accordingly[183].

金河生物科技股份有限公司 2018 年第一季度报告正文 证券代码：002688 证券简称：金河生物 公告编号：2018-034 金河生物科技股份有限公司 2018 年第一季度报告正文 1 金河生物科技股份有限公司 2018 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人王东晓、主管会计工作负责人牛有山及会计机构负责人(会计主 管人员)周立航声明：保证季度报告中财务报表的真实、准确、完整。 2 金河生物科技股份有限公司 2018 年第一季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 非经常性损益项目和金额 √ 适用 □ 不适用 单位：元 | 项目 | 年初至报告期期末金额 | 说明 | | --- | --- | --- | | 非流动资产处置损益（包括已计提资产减值准备的冲销部分） | 139,710.61 | | | 计入当期损益的政府补助（与企业业务 ...

Financial Performance - The company's operating revenue for 2017 was CNY 1,457,826,359.89, a decrease of 2.53% compared to CNY 1,495,686,256.40 in 2016[16] - The net profit attributable to shareholders for 2017 was CNY 108,423,892.06, down 33.94% from CNY 164,129,151.92 in 2016[16] - The net profit after deducting non-recurring gains and losses was CNY 95,070,633.81, a decline of 41.67% compared to CNY 162,982,205.94 in the previous year[16] - The net cash flow from operating activities was CNY 27,253,028.88, a significant drop of 90.68% from CNY 292,411,555.48 in 2016[16] - The basic earnings per share for 2017 was CNY 0.17, down 34.62% from CNY 0.26 in 2016[16] - The total revenue for Q4 2023 reached approximately ¥492.45 million, marking a substantial increase compared to previous quarters[20] - The net profit excluding non-recurring gains and losses in Q3 2023 was approximately ¥14.30 million, reflecting a decline compared to earlier quarters[20] - The company reported a government subsidy of approximately ¥15.97 million in 2017, contributing positively to its financial performance[21] Assets and Investments - The total assets at the end of 2017 were CNY 2,959,911,864.10, an increase of 11.18% from CNY 2,662,337,623.01 at the end of 2016[16] - The net assets attributable to shareholders at the end of 2017 were CNY 1,526,518,658.25, a slight increase of 2.01% from CNY 1,496,388,507.06 in 2016[16] - Equity assets increased by 608,400 CNY, a growth of 78.39%, mainly due to the investment in the joint venture Codiagro by the subsidiary Farmawei[33] - Fixed assets increased by 47,740,800 CNY, a growth of 7.11%, primarily due to the completion of projects such as the Jinhe Environmental Protection Phase III and the renovation of the vaccine production line by subsidiary Hangzhou Youben[33] - Cash and cash equivalents increased by 105,910,000 CNY, a growth of 44.24%, mainly to supplement liquidity after providing guarantees for Farmawei's external loan business[33] Business Operations and Strategy - The company has expanded its business scope to include the production of additive premixed feed since 2015[15] - The company is focusing on expanding its product line in feed additives, with an emphasis on high-quality and safe products to meet increasing market demand[29] - The company has engaged in a series of mergers and acquisitions to establish a strategic layout in the animal health product industry, including feed additives and veterinary pharmaceuticals[25] - The veterinary vaccine industry is experiencing rapid growth due to increased awareness of disease prevention in livestock and stricter food safety regulations[30] - The company is positioned to capitalize on the growing demand for environmental services, driven by stricter regulations and increased investment in pollution control[31] - The company plans to invest 600 million RMB to build an animal vaccine industrial base to expand production capacity and enhance profitability[49] Research and Development - The company is advancing the R&D and registration of new products such as bacteriocins and salinomycin in the U.S. market, and has established a new subsidiary focused on animal nutrition feed additives[46] - The company has established four major technology platforms in the vaccine business, enhancing its core competitive advantage in product technology[37] - The company plans to accelerate the research and development of new products such as brucellosis live vaccine and rabies vaccine, targeting to achieve one new product per year[104] - The company has allocated 200 million RMB for research and development in 2018, focusing on innovative veterinary solutions[185] Market Performance - The feed additive business generated main business revenue of 979.03 million RMB, a year-on-year decrease of 9.14%, accounting for 67.89% of main business revenue[45] - Revenue from animal feed additives was CNY 979 million, accounting for 67.16% of total revenue, down 9.14% from CNY 1.08 billion in 2016[56] - Revenue from veterinary biological products surged by 127.69% to CNY 94.25 million, up from CNY 41.39 million in 2016[56] - Domestic sales increased by 32.13% to CNY 928.79 million, while international sales fell by 33.27% to CNY 529.03 million[56] Human Resources and Corporate Governance - The company emphasizes talent acquisition and development, ensuring a strong human resource foundation for rapid growth[41] - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 721.22 million CNY[190] - The company has a structured governance framework with a clear delineation of roles among its board members and executives[179] - The company has established a comprehensive employee protection system, focusing on improving working conditions and increasing employee wages[152] Compliance and Risk Management - The company has ensured compliance with regulations regarding the storage, use, management, and disclosure of raised funds, with no violations reported[94] - The company is facing risks related to rising raw material prices, particularly corn, which significantly impacts product costs[106] - The company is also exposed to risks from exchange rate fluctuations affecting its overseas sales revenue[106] Shareholder Information - The cash dividend for 2017 is proposed at RMB 0.30 per 10 shares, totaling RMB 19,058,689.65, with a retained profit of RMB 301,518,732.56 to be carried forward[115] - The cash dividend payout ratio for 2017 is 17.58% of the net profit attributable to shareholders[115] - The total number of ordinary shareholders at the end of the reporting period was 38,830, an increase from 36,444 at the end of the previous month[168] - The largest shareholder, Inner Mongolia Jinhai Construction Installation Co., Ltd., holds 38.05% of the shares, totaling 241,758,600 shares, with 97,590,000 shares pledged[169] Environmental Responsibility - The company has maintained compliance with environmental regulations, ensuring that all pollutants are discharged within the legal limits[154] - The company’s subsidiary, Jinhe Environmental Protection, has treated wastewater with an inflow COD of approximately 10,000 mg/L, reducing it to around 50 mg/L post-treatment, showcasing its leadership in environmental management[154] - Jinhe Environmental Protection has been recognized as a "demonstration base for third-party environmental pollution control" by local environmental authorities, reflecting its commitment to sustainable practices[155]

Financial Performance - Operating revenue decreased by 7.31% to CNY 324,723,153.51 for the current period, and by 7.80% to CNY 965,374,706.05 year-to-date[8] - Net profit attributable to shareholders decreased by 23.23% to CNY 22,449,131.06 for the current period, and by 19.61% to CNY 99,258,351.08 year-to-date[8] - Net profit after deducting non-recurring gains and losses dropped by 66.64% to CNY 8,755,065.60 for the current period[8] - Basic and diluted earnings per share both decreased by 20.00% to CNY 0.04[8] - Weighted average return on equity fell to 1.54%, down 0.30% from the previous year[8] - Net cash flow from operating activities was negative at CNY -23,159,502.89, a decrease of 133.40% compared to the same period last year[8] - Net cash flow from operating activities decreased by CNY 86,237,511.31, a decline of 83.07%, attributed to lower sales performance[22] Assets and Liabilities - Total assets increased by 9.35% to CNY 2,911,389,818.19 compared to the end of the previous year[8] - Accounts receivable increased by CNY 14,410,562.76, a growth of 72.78%, due to an increase in customers using bank acceptance bills for payment[16] - Prepayments rose by CNY 106,291,604.23, a growth of 166.94%, primarily due to increased advance payments for raw materials[16] - Other receivables increased by CNY 46,098,555.74, a growth of 418.15%, mainly from patent technology transfer payments and increased loans to subsidiaries[16] - Short-term borrowings increased by CNY 231,674,500.00, a growth of 78.18%, to supplement insufficient working capital[17] - Financial expenses increased by CNY 34,670,161.81, a growth of 406.30%, due to higher average bank borrowings and reduced exchange gains[20] Cash Flow - Cash received from investment increased by CNY 6,045,879.44, a growth of 30.23%, due to increased maturity of bank wealth management products[22] - Cash paid for fixed assets and other long-term assets increased by CNY 41,199,275.31, a growth of 53.00%, due to increased environmental investments[22] - Cash received from borrowings increased by CNY 175,301,448.54, a growth of 33.98%, due to insufficient working capital from reduced sales revenue[23] - Other comprehensive income decreased by CNY 5,504,397.90, a decline of 98.17%, mainly due to the impact of RMB appreciation on foreign subsidiary financial statements[19] Shareholder Information - The total number of shareholders at the end of the reporting period was 37,821[12] - The largest shareholder, Inner Mongolia Jinhai Construction Installation Co., Ltd., holds 38.05% of the shares[12] Strategic Developments - The company is currently in a strategic investment phase for its animal vaccine business, resulting in lower-than-expected performance contributions[30] - The U.S. market is experiencing a decline in overall sales due to changes in the method of adding feed-grade antibiotics, impacting the company's revenue[30] - The company has established a new subsidiary, Inner Mongolia Jinhai Animal Nutrition Technology Co., Ltd., with a registered capital of RMB 20 million, where the company holds a 67% stake[30] - The company approved an investment of approximately RMB 35 million for the construction and operation of a wastewater treatment plant in Inner Mongolia[30] Compliance and Governance - The company has no overdue commitments from actual controllers, shareholders, or related parties during the reporting period[28] - There are no violations regarding external guarantees during the reporting period[31] - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[32] - The company has not conducted any research, communication, or interview activities during the reporting period[33] Future Projections - The estimated net profit attributable to shareholders for 2017 is projected to be between RMB 131.30 million and RMB 196.95 million, reflecting a change of -20% to 20% compared to the previous year[30] - The net profit for 2016 attributable to shareholders was RMB 164.13 million[30]

Financial Performance - The company's operating revenue for the first half of 2017 was CNY 640,651,552.54, a decrease of 8.04% compared to CNY 696,658,310.42 in the same period last year[17]. - The net profit attributable to shareholders of the listed company was CNY 76,809,220.02, down 18.49% from CNY 94,227,913.92 year-on-year[17]. - The net cash flow from operating activities was CNY 23,379,329.00, representing a significant decline of 72.96% compared to CNY 86,457,337.42 in the previous year[17]. - Basic earnings per share decreased by 20.00% to CNY 0.12 from CNY 0.15 in the same period last year[17]. - The company reported a significant decrease in net profit after deducting non-recurring gains and losses, which was CNY 72,912,445.69, down 21.72% from CNY 93,143,873.69 in the previous year[17]. - The weighted average return on net assets was 5.06%, down from 6.44% in the same period last year, a decrease of 1.38%[17]. - The company achieved operating revenue of 640.65 million yuan, a decrease of 8.04% compared to the same period last year[33]. - The operating profit was 91.08 million yuan, down 20.65% year-on-year, while the net profit attributable to shareholders was 76.81 million yuan, a decrease of 18.49%[33]. - The gross profit margin for the main business was 36.84%, an increase of 2.23 percentage points year-on-year, with the feed-grade chlortetracycline margin at 43.41%, up 1.82 percentage points[35]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,785,440,042.13, an increase of 4.62% from CNY 2,662,337,623.01 at the end of the previous year[17]. - The net assets attributable to shareholders of the listed company decreased by 1.53% to CNY 1,473,526,208.58 from CNY 1,496,388,507.06 at the end of the previous year[17]. - The company's total assets at the end of the reporting period were CNY 2,785,440,042.13, an increase from CNY 2,662,337,623.01 at the beginning of the period[140]. - Current assets totaled CNY 996,106,547.26, up from CNY 865,202,870.27 at the beginning of the period, reflecting a growth of approximately 15.1%[138]. - The company's total liabilities increased to CNY 1,227,726,142.95 from CNY 1,078,206,185.58, indicating a growth of about 13.9%[139]. - The company's equity attributable to shareholders decreased to CNY 1,473,526,208.58 from CNY 1,496,388,507.06, a decline of approximately 1.5%[140]. - The company’s inventory rose to CNY 347.68 million, accounting for 12.48% of total assets, an increase from 11.28% year-on-year[51]. - Short-term loans increased to CNY 446.33 million, representing 16.02% of total assets, up from 11.13% in the previous year[51]. Cash Flow - The net cash flow from operating activities was ¥23.38 million, a decrease of 72.96% year-on-year, attributed to reduced operating income and increased employee-related expenditures[38]. - The net cash flow from investment activities was -¥150.52 million, an increase of 11.25% compared to the previous year, mainly due to the maturity of bank wealth management investments[38]. - The net cash flow from financing activities was ¥22.59 million, a decrease of 86.83% year-on-year, primarily due to the absence of similar fundraising activities as in the previous year[38]. - The cash inflow from operating activities totaled CNY 709,693,468.43, down from CNY 751,016,467.60 in the previous year, a decline of 5.5%[155]. - The company incurred financial expenses of CNY 1,617,367.93, compared to a financial income of CNY 10,660,205.33 in the previous year, indicating a significant shift in financial performance[150]. Investments and Acquisitions - The company’s subsidiary, PHARMGATE LLC, completed the acquisition of 100% of the shares of the U.S. company, ProTech, expanding into the veterinary vaccine sector[34]. - The company is investing 50 million yuan in the FDA registration fees for new veterinary drug applications and related expenditures to enter the U.S. terminal market[62]. - The company has completed the construction of a new pressure station system and upgraded the feed-grade gold mycin product to meet market demands[62]. - The company is actively exploring external business expansion in the environmental protection sector, laying a foundation for sustainable development[34]. - The company has expanded its market presence through acquisitions, including the acquisition of Hohhot Jinsheng Water Co., Ltd. for wastewater treatment operations[177]. Research and Development - Research and development investment increased by 100.44% to ¥24.58 million, reflecting the company's commitment to enhancing technological innovation and new product development[40]. - The company is focusing on research and development of new technologies to drive future growth and innovation[165]. - The company is investing in new product development and technology integration, although the performance has not yet effectively materialized[73]. Market Performance - Domestic sales accounted for 56.70% of total revenue, increasing by 24.73% year-on-year, while international sales decreased by 31.58% to 43.30% of total revenue[43]. - Revenue from veterinary biological products increased by 571.97% compared to the same period last year, primarily due to the acquisition of 100% equity in U.S. company Putech in October of the previous year[47]. - The company reported a total revenue of 19,986.71 million yuan for the first half of 2017, with a net profit of 1,640.25 million yuan, reflecting a significant performance in the market[96]. Compliance and Governance - The company has ensured compliance in the storage, use, management, and disclosure of raised funds, with no violations reported[64]. - The company has not violated any commitments related to competitive practices during the reporting period[82]. - The company reported no major violations of commitments during the reporting period, and all commitments are being strictly adhered to[84]. - The company has not undergone any bankruptcy restructuring during the reporting period[86]. - There are no significant litigation or arbitration matters affecting the company, and the arbitration result regarding a dispute with Zhejiang Jianliang Bioengineering Co., Ltd. is not expected to have a major impact on the company's profits[88]. Shareholder Information - The total number of shares decreased from 635,289,655 to 632,320,282 due to the release of restricted shares, resulting in a reduction of limited shares from 16.79% to 16.17%[116]. - The number of shareholders holding more than 5% of ordinary shares was reported at 32,683 at the end of the reporting period[122]. - The company has a significant shareholder structure, with the top ten shareholders holding a substantial portion of the total shares, indicating concentrated ownership[124]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period[125]. Environmental and Social Responsibility - The company is classified as a key pollutant discharge unit by environmental protection authorities[109]. - The actual discharge of chemical oxygen demand (COD) was approximately 175 tons per year, with a total COD discharge of 350 tons per year[109]. - The company’s subsidiary, Jinhe Environmental Protection, operates as a third-party pollution control demonstration base[109].